Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Q1 Losses Up on Increased Spending

Premium

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week reported its first-quarter financial results, posting a jump in its net loss due to higher costs associated with drug development and its recently completed initial public offering.

For the three-month period ended March 31, 2014, Dicerna's net loss climbed to $10.8 million from $3.8 million in the same period a year earlier.

Research and development spending rose to $5.3 million from $2.4 million, largely due to the initiation of Phase I testing for the company's RNAi cancer drug DCY-MYC in April, as well as continued work on its primary hyperoxaluria 1 therapy DCR-PH1, which is slated to enter human trials early next year.

General and administrative expenses increased to $2.8 million from $1.1 million, reflecting Dicerna's costs of completing its IPO in January.

At the end of the first quarter, Dicerna had cash and cash equivalents totaling $133.8 million.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.